Antibody-drug conjugates can deliver chemotherapy directly to tumors but more than 95 percent of the dose often ends up in healthy tissues, decreasing efficacy and increasing toxicity. Mythic Therapeutics FateControl technology improves the uptake of ADCs in cancerous cells while avoiding the release of their toxic payloads in healthy ones. This promises to increase efficacy of these therapies in a wide range of cancers without causing unacceptable side-effects. We spoke to Brian Fiske, co-founder, chief scientific officer of Mythic, about the challenges that have held back the benefits of ADCs, how the company’s FateControl technology addresses those, and how it is thinking of building a pipeline of ADCs across indications.
The Year in Biotech and What’s Ahead in 2021
Bringing Precision Cancer Care to Dogs
As COVID-19 Vaccines Ship, One Company Brings Innovation to the Vials
Advancing an Antibody to Prevent and Treat Cytokine Storms in COVID-19
Using AI Created Digital Twins to Accelerate Clinical Trials
Modulating RNA to Quell Disease
A Quest to Extend Life through Early Disease Detection
Modulating a Gatekeeper of Cellular Metabolism to Treat a Range of Diseases
Finding the Best Cell for the Job
Transforming Clinical Trials with Digital Technology
Designing Immunotherapies that Can Overcome Recurrence and Resistance
Extending Precision Medicine Beyond Cancer
Growing Biologics
An Experimental COVID-19 Vaccine Begins Human Clinical Trials
Speeding the Delivery of CAR-T Therapies While Cutting the Cost
Transforming Infused Biologics into Injectables
A Novel Approach to NASH That May Have Benefits for COVID 19 As Well
Will a Focus on Protein Dysregulation Help Prothena Break from the Fold
After FDA Set Back, AI Driven Drug Company Advances with New CEO
A Gamified Therapy System Helps People with Brain Injury Recover
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
Ground Truths